Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature

BJU International

Volumn 114, Issue 6, 2014, Pages E120-E129

  Faisal, Farzana A ^a   Sundi, Debasish ^a   Pierorazio, Phillip M ^a   Ball, Mark W ^a   Humphreys, Elizabeth B ^a   Han, Misop ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Ballentine Carter, H ^a   Bivalacqua, Trinity J ^a   Schaeffer, Edward M ^a   Ross, Ashley E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

outcome; prostate cancer; prostate specific antigen; prostatectomy; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE CLASSIFICATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SURGICAL TECHNIQUE; BLOOD; CANCER GRADING; DISEASE FREE SURVIVAL; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84920159050     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12771     Document Type: Article

References (23)

1. D'Amico AV, Whittington R, Malkowicz SB, etal. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
2. Pierorazio PM, Ross AE, Han M, etal. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU Int 2011; 109: 988-993
3. D'Amico AV, Cote K, Loffredo M, etal. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: 1320-1324
4. Walz J, Joniau S, Chun FK, etal. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010; 107: 765-770
5. D'Amico AV, Chen MH, Catalona WJ, etal. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 2007; 110: 56-61
6. Stamey TA, Yemoto CM, McNeal JE, etal. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000; 163: 1155-1160
7. Stamey TA, McNeal JE, Yemoto CM, etal. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-1400
8. Olumi AF, Richie JP, Schultz DJ, etal. Calculated volume of prostate cancer identifies patients with clinical stage T1c disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study. Urology 2000; 56: 273-277
9. Hernandez DJ, Nielsen ME, Han M, etal. Contemporary evaluation of the D'Amico risk classification of prostate cancer. Urology 2007; 70: 931-935
10. Epstein JI, Pizov G, Walsch PC,. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593
11. Epstein JI, Walsh PC, Carmichael M, etal. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
12. Tosoian JJ, Trock BJ, Landis P, etal. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
13. Thomsen FB, Brasso K, Klotz LH, etal. Active surveillance for clinically localized prostate cancer: a systematic review. J Surg Oncol 2014; 109: 830-835
14. Reese AC, Landis P, Han M, etal. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013; 190: 2033-2038
15. D'Amico AV, Renshaw AA, Arsenault L, etal. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 1999; 45: 841-846
16. Mehta V, Rycyna K, Baesens BM, etal. Predictors of Gleason score upgrading on subsequent prostatectomy: a single institution study in a cohort of patients with GS 6. Int J Clin Exp Pathol 2012; 5: 496-502
17. Kulkarni GS, Lockwood G, Evans A, etal. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007; 109: 2432-2438
18. Vora A, Large T, Aronica J, etal. Predictors of Gleason score upgrading in a large African-American population. Int Urol Nephrol 2013; 45: 1257-1262
19. Sundi D, Kryvenko ON, Carter HB, etal. Pathological examination of radical prostatectomies in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol 2014; 191: 60-67
20. Koppie TM, Bianco FJ Jr, Kuroiwa K, etal. The clinical features of anterior prostate cancers. BJU Int 2006; 98: 1167-1171
21. Lawrentschuk N, Haider MA, Daljeet N, etal. Prostatic evasive anterior tumors: the role of magnetic resonance imaging. BJU Int 2009; 105: 1231-1236
22. Komai Y, Numao N, Yoshida S, etal. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol 2013; 190: 867-873
23. Cirillo S, Petracchini M, Della Monia P, etal. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008; 63: 871-879